However, DR-10,624, a GLP-1/GCG/fibroblast growth factor 21 (FGF-21) triple agonist is under investigation for individuals with severe hypertriglyceridemia (not limited to individuals with obesity; NCT06555640). Here, FGF21 is linked to hypertriglyceridemia.